Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

May 01, 2025 at 08:30 AM EDT

The TIME Precision Network is a newly-formed group of investigators across TIME’s provider site network dedicated to supporting Phase I trials

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials.

The TIME Network is powered to efficiently enroll patients within its participating data-integrated site base, in which patients are identified and matched to trials and sites are activated within days or weeks. At the Taylor Cancer Research Center (TCRC), Tempus activated the site in approximately two weeks for the Nimbus 9216-101 study, and enrolled its first patient within one month of site activation. For the Pathos P300-02-001 study, Tempus screened and enrolled the trial’s first and second patients at Nebraska Cancer Specialists and Oncology Consultants within weeks.

“The integration of phase I clinical trial sites adds a critical capability to the TIME Network. We are now able to activate and efficiently execute these early studies that are fundamental to drug development and such a valuable offering to patients.” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “The reality is that these studies require specific and coordinated infrastructure to be successful, and I am proud that Tempus can now work with these sites and our life science partners to enroll patients into these cutting-edge clinical trials.”

“It’s a privilege for us at the TCRC to be able to work with Tempus in engaging new precision trial opportunities for our cancer patients,” stated John Nemunaitis, Chief Scientific Officer, Taylor Cancer Research Center. “Through the relationship of our community oncology, not-for-profit program and Tempus, a seamless process has been established to implement study activation and rapidly engage patient start up. As an example, we were the first to safely administer a novel WRN inhibitor by Nimbus within a global trial to a cancer patient. Additional patients have been evaluated and are now proceeding with the enrollment process.”

Tempus has spent years building a robust network of provider sites, including many community hospitals that serve underrepresented patient groups, with the aim of expanding access to clinical trials for patients in communities across the country. TIME is significantly reducing barriers to clinical trial participation, enabling easier access to investigational therapies for patients.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of TIME and its clinical trial solutions on patients, providers and sponsors, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.